Anuncio
Anuncio
APRE
Aprea Therapeutics, Inc. Common stock
0.94
USDPatrocinado
0.00
+0.52%
09 ene, 14:49 UTC -5
Cerrado
Post-mercado
0.95
0.00
+0.21%
Informes de beneficios de APRE
Ratio de Sorpresa Positivo
APRE superó 16 de las últimas 24 estimaciones.
67%
Próximo informe
Fecha del próximo informe
23 mar 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.36
Cambio implícito desde Q3 25 (Revenue/ EPS)
-100.00%
/-23.40%
Cambio implícito desde Q4 24 (Revenue/ EPS)
-100.00%
/-26.53%
Aprea Therapeutics, Inc. Common stock earnings per share and revenue
On 12 nov 2025, APRE reported earnings of -0.47 USD per share (EPS) for Q3 25, missing the estimate of -0.34 USD, resulting in a -36.11% surprise. Revenue reached 2.00 mil, compared to an expected --, with a 0.00% difference. The market reacted with a -4.55% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analistas forecast an EPS of -0.36 USD, with revenue projected to reach -- USD, implying an reducir of -23.40% EPS, and reducir of -100.00% in Revenue from the last quarter.
Preguntas frecuentes
What were Aprea Therapeutics, Inc. Common stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Aprea Therapeutics, Inc. Common stock reported EPS of -$0.47, missing estimates by -36.11%, and revenue of $2.00K, 0% as expectations.
How did the market react to Aprea Therapeutics, Inc. Common stock's Q3 2025 earnings?
The stock price moved down -4.55%, changed from $1.32 before the earnings release to $1.26 the day after.
When is Aprea Therapeutics, Inc. Common stock expected to report next?
The next earning report is scheduled for 23 mar 2026.
What are the forecasts for Aprea Therapeutics, Inc. Common stock's next earnings report?
Based on 5
analistas, Aprea Therapeutics, Inc. Common stock is expected to report EPS of -$0.36 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Cheque FXEmpire's Earnings Calendar for today's list of reporting companies.
Anuncio